{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-barrier-methods-spermicides/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"4376cd4a-8b80-5ac2-906d-1325fe3495e7","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 48911f48-fcfe-4acc-8ec4-9d32b73b077c --><h2>Changes</h2><!-- end field 48911f48-fcfe-4acc-8ec4-9d32b73b077c -->","summary":null,"htmlStringContent":"<!-- begin item 52b97657-762a-4189-969b-cbc2364de756 --><!-- begin field 31cf976b-c607-4dcd-9e70-61dd5a0e9981 --><p><strong>March to April 2016</strong> — reviewed. A literature search was conducted in March 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor structural changes have been made.</p><!-- end field 31cf976b-c607-4dcd-9e70-61dd5a0e9981 --><!-- end item 52b97657-762a-4189-969b-cbc2364de756 -->","topic":{"id":"7e2ddebd-77b3-5f0f-b2ec-c79dbadaf3a2","topicId":"f563065a-9aa2-4d22-8b95-070dbf653f5e","topicName":"Contraception - barrier methods and spermicides","slug":"contraception-barrier-methods-spermicides","lastRevised":"Last revised in April 2016","chapters":[{"id":"588be988-d8e5-5d27-ad0a-aa8bbd7b148f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0da9669-ecaa-5eae-97a4-34ad2e8ae264","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2c7a9f7a-bb6d-5988-8ddb-cb6e1e6ada15","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4376cd4a-8b80-5ac2-906d-1325fe3495e7","slug":"changes","fullItemName":"Changes"},{"id":"49314716-93a9-5d83-b256-69788cbd1456","slug":"update","fullItemName":"Update"}]},{"id":"252a8207-12dc-502d-9712-de00afa1e34a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2839f2a6-a7e5-5517-ad7f-d87c516d72c6","slug":"goals","fullItemName":"Goals"},{"id":"82c8234c-c169-5ad5-a09d-c9d107054112","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"74d95b8e-fb23-5dfd-a9bb-356501fbdf45","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"254e8592-3bc6-5d1d-b35d-fb513a9fc457","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"11d859eb-e7e6-5d59-bf72-1b0ce0ddfff2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3451c4f8-8795-5525-9525-8a19a50bd4e9","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"ecef055c-fa88-5e82-8121-e9b73f5f1981","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46e7533b-910e-5cea-8d1a-e8a7a1e41058","slug":"where-to-get-barrier-contraception","fullItemName":"Where to get barrier contraception"}]},{"id":"3b18e49a-05a1-5a9f-aefc-4e6e5feae171","fullItemName":"Management","slug":"management","subChapters":[{"id":"75e63100-2ae4-5726-ab72-09819a09a315","slug":"male-female-condoms","fullItemName":"Scenario: Male and female condoms"},{"id":"4bc29c29-2cd4-5b96-a87c-c17486403057","slug":"diaphragms-caps","fullItemName":"Scenario: Diaphragms and caps"},{"id":"5b3dcbd7-e1f7-5307-9d7d-f53eadc1cf00","slug":"spermicides","fullItemName":"Scenario: Spermicides"}]},{"id":"0f7230ec-fa9e-5a8e-b8a4-ee182e60e64c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dd334852-d6c1-5bb0-aeb2-c5ca02c6e073","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c2b84699-3a93-5521-94f2-5271f6daa8b4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d3b6d176-ae7e-5fbf-8353-cc50765497cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7f4163e7-cd12-5458-8911-3ed6fe1070f3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a33a8821-7751-5091-b418-23e3c07cc662","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"109e7207-750b-5db5-b225-edf2bb350ba2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"712b3e66-8ca4-52b6-a04f-07bcb23bf527","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c7a9f7a-bb6d-5988-8ddb-cb6e1e6ada15","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e02928bc-2d25-50cf-baf6-2076f3ddb862","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field bf522fed-c120-4694-8042-c1a83758e197 --><h3>Previous changes</h3><!-- end field bf522fed-c120-4694-8042-c1a83758e197 -->","summary":null,"htmlStringContent":"<!-- begin item 45b6000f-9d23-498b-ad67-e1a5cb26958b --><!-- begin field 0aa95470-1535-4dd9-bec0-a27ed43d9c48 --><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2013</strong> – minor update. The telephone number for NHS Direct has been updated.</p><p><strong>February to June 2012</strong> — reviewed. A literature search was conducted in December 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. However, recommendations have been rewritten for clarity, and superseded guidelines and manufacturers' Summary of Product Characteristics have been updated accordingly.</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. Issued in June 2011.</p><p><strong>December 2010</strong> — minor update. Type B diaphragms BS 4028 Type 1 (coil spring) are no longer listed in the Drug Tariff. Prescriptions have been removed. Note that the Milex omniflex® coil spring diaphragms are still available to prescribe. Issued in January 2010.</p><p><strong>February 2010 </strong>— updated to include the revised UK medical eligibility criteria for contraceptive use, as published by the Faculty of Sexual and Reproductive Healthcare (FSRH), formerly the Faculty of Family Planning and Reproductive Healthcare (FFPRHC). Issued in January 2010.</p><p><strong>March 2009</strong> — minor update. The Quality and Outcomes Framework (QOF) indicators for sexual health have been updated in the Goals and outcome measures section. Issued in April 2009.</p><p><strong>December 2008</strong> — minor update. All-flex® latex diaphragms (all sizes) have been discontinued. Text has been updated and prescriptions removed. Issued in January 2009.</p><p><strong>March 2008</strong> — minor update. Ortho-creme® has been discontinued. Prescriptions for Ortho-creme® have been removed and replaced with Gygel®. Issued March 2008.</p><p><strong>April to September 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2006</strong> — minor update. Information regarding orlistat and reduced efficacy of oral contraceptives included in drug interactions. Issued in July 2006.</p><p><strong>January 2006</strong> — minor update. Gynol II Jelly, Microval tablets and Duragel have been discontinued and the prescriptions have been removed. Black triangle removed from Cerazette®. Issued in February 2006.</p><p><strong>October 2005</strong> — updated to include the new recommendations on missed pills from the Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit, published in April 2005. Issued in November 2005.</p><p><strong>April 2005</strong> — minor update. Neogest® tablets have been discontinued and the prescriptions have been removed. Issued in April 2005.</p><p><strong>February 2005</strong> — updated to include prescribing advice from the Committee on Safety of Medicines on the effect of depot medroxyprogesterone acetate contraception on bones. Issued in February 2005.</p><p><strong>September 2004</strong> — updated to include the WHO Medical Eligibilty Criteria relating to contraception for 2004 and recent licence changes to Cerazette®. Delfen® Contraceptive Foam is being discontinued at the end of October 2004 and the prescriptions have been removed. Issued in September 2004.</p><p><strong>January 2004</strong> — reviewed. Validated in March 2004 and issued in June 2004.</p><p><strong>January 2001</strong> — rewritten. Validated in March 2001 and issued in June 2001. Guidance on emergency contraception is no longer included in the Contraception guidance but can be found as a separate CKS topic.</p><p><strong>December 1997</strong> — written.</p><!-- end field 0aa95470-1535-4dd9-bec0-a27ed43d9c48 --><!-- end item 45b6000f-9d23-498b-ad67-e1a5cb26958b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}